Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiac Science Inc. DFIB (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Ibexx who wrote (30)	11/15/2001 6:35:55 AM
From: Marc Phelan	Respond to of 174

Earnings are out: biz.yahoo.com For the nine months ended September 30, 2001, revenue was $2.9 million versus $2.8 million in the first nine months of last year. Sales of disposable defibrillator electrodes for this period grew by 476 percent over last year's corresponding period. The net loss for this year's first nine months was $20.4 million, or $0.81 loss per share, versus a net loss of $25.6 million, or $1.47 loss per share in the comparable prior year period. President and CEO Raymond W. Cohen said the third quarter marked the most dramatic change and progress in the history of Cardiac Science. He also noted that developments during the quarter have created a significant and positive inflection in both revenue and cash flow. ``The accelerating awareness and demand for our unique Powerheart technology is very encouraging. Our mission of becoming a new standard of care for the monitoring and treatment of cardiac patients at risk of sudden cardiac arrest in hospitals is now shared by a number of important thought leaders. This, combined with a growing body of positive clinical results is translating into numerous placement opportunities in US hospitals and sales in the international market.'' ``Even more powerful in the near term will be the impact of our acquisition of Survivalink, a leading supplier of automated external defibrillators (AEDs), which we closed at the end of the quarter,'' said Cohen. ``Currently, the AED product line is at a revenue run rate of $2 million per month with substantial upside based on a rapidly growing market and the planned increase of sales personnel and resources to this important sector.'' President sounds upbeat!

To: Ibexx who wrote (30)	11/27/2001 2:33:37 PM
From: Ibexx	Read Replies (1) \| Respond to of 174

Stock should gain substantially in the months to come on the strength of the following merger: Cardiac Science's Offer to Acquire Artema Medical Accepted; Final Exchange of Shares Scheduled for November 30 PR NEWSWIRE, 11/27/2001 2:00:00 AM IRVINE, Calif., Nov 27, 2001 /PRNewswire via COMTEX/ -- Cardiac Science, Inc (Nasdaq: DFIB) today announced that its offer to acquire all the issued and outstanding shares of Stockholm-based Artema Medical AB, a manufacturer of patient monitors and external defibrillator devices, has been accepted by 94.7 percent of Artema shareholders and that all other conditions to the acquisition have been met. As consideration, Cardiac Science will issue approximately 4 million shares of common stock to Artema shareholders. The final settlement and exchange of shares is anticipated to take place on November 30 for those Artema shareholders who tendered their shares during the acceptance period, which ended on November 23. Cardiac Science will immediately begin the process of a compulsory acquisition of the remaining shares in Artema and file an application for de-listing of the Artema shares from the Stockholm exchange as soon as possible. According to Cardiac Science President and CEO, Raymond W. Cohen, "The acquisition of Artema provides us with a number of significant benefits including the expansion of our in-hospital defibrillator product line, enhanced distribution in Europe, the Middle East and Asia, as well as an installed base of about 6,000 patient monitors, which we believe will be excellent prospects for our new Powerheart(R) Cardiac Rhythm Module that automatically treats patients who suffer life-threatening heart rhythms." About Cardiac Science Cardiac Science develops, manufactures and markets life-saving external cardiac defibrillator devices and proprietary disposable defibrillator electrodes that monitor and automatically treat patients who suffer life-threatening heart rhythms. Powerheart(R), the Company's patented hospital bedside defibrillator and Survivalink(R)-brand Automated External Defibrillators (AEDs) are marketed in the United States by its 36-person direct sales force and by international distributors in 40 countries around the world. For more information on Cardiac Science, please visit www.cardiacscience.com. For additional investor information please visit www.allencaron.com. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2000 and other documents filed by the company with the Securities and Exchange Commission. WE HAVE FILED AN S-4 REGISTRATION STATEMENT WITH THE SEC IN CONNECTION WITH THE OFFER. WE URGE YOU TO READ THE REGISTRATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and stockholders are able to obtain free copies of these documents at the Commission's website at www.sec.gov and upon oral or written request to Cardiac Science, Inc, 16931 Millikan Avenue, Irvine, California, 92606, USA, Attention: Mr. Roderick de Greef, Chief Financial Officer (telephone number +1 949 587 0357). For further information, please contact: investors, Matt Clawson, matt@allencaron.com, or Lynn Johnson, lynn@allencaron.com, or media, Len Hall, len@allencaron.com, all of Allen & Caron Inc, +1-949-474-4300, for Cardiac Science, Inc; or Roderick de Greef, Executive VP & Chief Financial Officer of Cardiac Science, Inc, +1-949-587-0357, rdegreef@cardiacscience.com. Ibexx